Ikarian Capital, LLC Arcus Biosciences, Inc. Put Options Transaction History

Ikarian Capital, LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2022 Feb 14, 2023	BUY	$19.7 - $35.71 $5.58 Million - $10.1 Million	283,100 New	283,100 $5.85 Million
Q2 2022 Aug 12, 2022	SELL	$17.23 - $37.73 $1.29 Million - $2.81 Million	-74,600 Reduced 59.87%	50,000 $1.27 Million
Q4 2021 Feb 14, 2022	BUY	$31.38 - $48.47 $3.91 Million - $6.04 Million	124,600 New	124,600 $5.04 Million
Q3 2021 Nov 15, 2021	SELL	$26.93 - $37.68 $6.61 Million - $9.25 Million	-245,500 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$26.16 - $41.39 $5.89 Million - $9.31 Million	225,000 Added 1097.56%	245,500 $6.89 Million
Q4 2020 Feb 12, 2021	BUY	$17.0 - $32.36 $348,500 - $663,380	20,500 New	20,500 $532,000

201

51.7M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.13B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.